A Double-Blind, Doubly-Randomized, Placebo-Controlled Study of Intranasal Esketamine in an Adaptive Treatment Protocol to Assess Safety and Efficacy in Treatment-Resistant Depression (SYNAPSE)

Trial Profile

A Double-Blind, Doubly-Randomized, Placebo-Controlled Study of Intranasal Esketamine in an Adaptive Treatment Protocol to Assess Safety and Efficacy in Treatment-Resistant Depression (SYNAPSE)

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Dec 2017

At a glance

  • Drugs Esketamine (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Acronyms SYNAPSE
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 28 Dec 2017 Primary endpoint has been met. (Change from baseline to the 1-week endpoint in Montgomery Asberg Depression Rating Scale (MADRS) total score), according to a Janssen media release.
    • 28 Dec 2017 Results published in a Janssen media release.
    • 27 Dec 2017 Results assessing efficacy, safety and dose response of intranasal esketamine, published in the JAMA Psychiatry.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top